Skip to main content

Table 2 Inverse-variance weighted analysis of allelic associations

From: Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects

    

European Caucasian and low ancestry Polynesiand

High ancestry Polynesiane

Polynesianf

All ancestriesg

 

SNP

Chr:Posb

Effect/Otherc

ORh

P h

Het Ph

ORh

P h

Het Ph

ORh

P h

Het Ph

ORh

P h

Het Ph

(95% CI)

(95% CI)

(95% CI)

(95% CI)

1a

rs475414

11:64241844

T/C

1.02

0.862

0.990

1.15

0.233

0.727

1.12

0.270

0.839

1.07

0.376

0.861

(0.85,1.22)

(0.92,1.43)

(0.92,1.34)

( 0.93,1.23)

1

rs17299124

11:64256859

C/A

0.94

0.539

0.425

3.38

6.1 × 10,4

0.674

1.95

0.006

0.153

1.71

0.109

0.010

(0.76,1.16)

(1.69,6.79)

(1.21,3.15)

( 0.89,3.28)

2

rs693591

11:64325069

C/G

0.99

0.942

0.559

1.25

0.051

0.053

1.23

0.047

0.113

1.12

0.167

0.087

(0.78,1.26)

(1.00,1.57)

(1.00,1.51)

( 0.95,1.33)

2

rs17300741

11:64331462

A/G

1.08

0.402

0.446

1.04

0.793

0.173

1.10

0.469

0.254

1.07

0.396

0.388

(0.90,1.29)

(0.78,1.38)

(0.86,1.40)

( 0.92,1.24)

2

rs2078267

11:64334114

C/T

1.00

0.999

0.499

1.84

0.012

0.804

1.51

0.022

0.591

1.08

0.370

0.169

(0.84,1.20)

(1.14,2.95)

(1.06,2.14)

(0.91,1.28)

3

rs3825018

11:64358809

G/A

1.24

0.028

0.660

1.33

0.020

0.568

1.34

0.008

0.767

1.27

0.002

0.822

(1.02,1.50)

(1.05,1.69)

(1.08,1.66)

(1.10,1.48)

3

rs475688

11:64364291

T/C

1.31

0.011

0.360

0.95

0.683

0.216

1.03

0.768

0.096

1.13

0.109

0.093

(1.06,1.60)

(0.76,1.20)

(0.84,1.27)

(0.97,1.32)

3

rs7932775

11:64367862

C/T

1.32

0.017

0.923

1.21

0.095

0.256

1.23

0.051

0.412

1.26

0.004

0.550

(1.05,1.66)

(0.97,1.51)

(1.00,1.51)

(1.08,1.48)

3

rs476037

11:64369540

A/G

1.05

0.770

0.874

1.25

0.480

0.014

1.19

0.461

0.036

1.08

0.423

0.070

(0.78,1.40]

(0.67,2.34)

(0.75,1.89)

(0.89,1.31)

3

rs478607

11:64478063

G/A

1.33

0.020

0.371

1.04

0.785

0.148

1.13

0.337

0.109

1.19

0.056

0.167

(1.05,1.70)

(0.79,1.36)

(0.88,1.44)

(1.00,1.43)

4

rs12289836

11:65436888

A/G

0.87

0.156

0.435

0.89

0.327

0.717

0.91

0.423

0.791

0.88

0.085

0.863

(0.72,1.05)

(0.70,1.13)

(0.73,1.14)

(0.76,1.02)

4

rs642803

11:65560620

T/C

0.97

0.728

0.267

0.95

0.662

0.862

1.00

0.982

0.726

0.96

0.586

0.818

(0.81,1.16)

(0.76,1.19)

(0.81,1.23)

(0.84,1.11)

  1. aLD block as shown in Additional file 2: Figure S1 and S2, block 1: upstream, block 2: SLC22A11, block 3: SLC22A12, block 4: downstream. bBase position is according to Genome Reference Consortium human genome build 37 (GRCh37). cEffect/Other, effect allele and other allele, all odds ratios (ORs) are calculated relevant to the effect allele defined as the allele in-phase with rs3825018 G allele according to 1,000 genomes linkage disequilibrium data. dCombining EP(L) and NZ European Caucasian sample sets. eCombining the EP(H), WP and EP/WP sample sets. fCombining the Eastern Polynesian EP high (EP(H)), EP low (EP(L)), Western Polynesian (WP) and EP/WP sample sets. gCombining the EP(H), EP(L), WP, EP/WP and NZ European Caucasian sample sets. hOR: inverse-variance weighted analysis OR (adjusted for sex); P: inverse-variance weighted analysis P-value; Het P: heterogeneity P-value, inverse-variance weighted analyses were reanalyzed using a random-effects model if the Het P was <0.05.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us